|
Tindamax (Tinidazole Tablets)
 This product requires a valid prescription
| |
|
Type |
Strength |
|
Quantity |
|
Price (USD) |
|
|
|
Tindamax oral tablets are indicated for the treatment of trichomoniasis caused by T. vaginalis in both female and male patients. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection.
Tindamax oral tablets are indicated for the treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age.
Tindamax is a first-line therapy in the treatment of trichomoniasis, giardiasis, intestinal amebiasis, and amebic liver abscess. It is the first new therapy approved for trichomoniasis in nearly 40 years. Tindamax is a second-generation nitroimidazole (metronidazole is a first-generation nitroimidazole).
Tindamax oral tablets are indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage.
Patients undergoing hemodialysis: During hemodialysis, clearance of tinidazole is significantly increased; the half-life is reduced from 12.0 hours to 4.9 hours. Approximately 43% of the amount present in the body is eliminated during a 6-hour hemodialysis session. Thus, if tinidazole is administered on a day when dialysis is performed, it is recommended that an additional dose of tinidazole equivalent to one-half of the recommended dose be administered after the end of the hemodialysis.
Store at controlled room temperature 20-25º C (68-77º F); excursions permitted to 15-30º C (59-86º F) [see USP]. Protect contents from light.
|
|
|
|
